Cargando…

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis

In recent years, plasma cell-free DNA (cfDNA) has been attracting increasing attention as a potential tumor marker, as this method is easily applied and minimally invasive. A series of studies have confirmed the association between the level of cfDNA and overall survival (OS) in non-small-cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Zongbi, Liu, Binliang, Guan, Xiuwen, Ma, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5532691/ https://www.ncbi.nlm.nih.gov/pubmed/28781780 http://dx.doi.org/10.3892/mco.2017.1301

Ejemplares similares

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
por: Mo, Hongnan, et al.
Publicado: (2020)

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
por: Liu, Binliang, et al.
Publicado: (2018)

Clinical significance of plasma free DNA in patients with non-small cell lung cancer
por: Ma, Lanxiang, et al.
Publicado: (2019)

The molecular tumor burden index as a response evaluation criterion in breast cancer
por: Yi, Zongbi, et al.
Publicado: (2021)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease
por: Szpechcinski, A, et al.
Publicado: (2015)

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers
por: Yi, Zongbi, et al.
Publicado: (2020)

Cell-free DNA in non-small cell lung cancer
por: Gedvilaitė, Vaida, et al.
Publicado: (2017)

Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancer
por: Hyun, Myung Han, et al.
Publicado: (2017)

Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients
por: Kageyama, Shun-ichiro, et al.
Publicado: (2018)

Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma
por: Raman, Lennart, et al.
Publicado: (2020)

Multi-omics fusion analysis models with machine learning predict survival of HER2-negative metastatic breast cancer: a multicenter prospective observational study
por: Wang, Jiani, et al.
Publicado: (2023)

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells
por: Guan, Xiuwen, et al.
Publicado: (2016)

Correction: Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients
por: Kageyama, Shun-Ichiro, et al.
Publicado: (2018)

Aberrant Methylation of SLIT2 Gene in Plasma Cell-Free DNA of Non-Small Cell Lung Cancer Patients
por: Kim, Yujin, et al.
Publicado: (2022)

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016)

Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore, Vidya H, et al.
Publicado: (2018)

Association between plasma fibrinogen and survival in patients with small‐cell lung carcinoma
por: Fan, Shanshan, et al.
Publicado: (2017)

Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients
por: Liu, Binliang, et al.
Publicado: (2020)

Monitoring early dynamic changes of plasma cell-free DNA and pretreatment pre-albumin to predict chemotherapy effectiveness and survival outcomes in advanced non-small cell lung cancer
por: Chen, Jia, et al.
Publicado: (2022)

Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients
por: Mondelo-Macía, Patricia, et al.
Publicado: (2022)

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung Cancer
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2021)

The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis
por: Wang, Fei, et al.
Publicado: (2015)

Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients
por: Yue, Dongsheng, et al.
Publicado: (2022)

Plasma cell-free DNA methylation combined with tumor mutation detection in prognostic prediction of patients with non-small cell lung cancer (NSCLC)
por: Guo, Dan, et al.
Publicado: (2020)

Plasma Cell‐Free DNA Genotyping: From an Emerging Concept to a Standard‐of‐Care Tool in Metastatic Non‐Small Cell Lung Cancer
por: Gray, Jhanelle, et al.
Publicado: (2021)

Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients
por: Bach, Sander, et al.
Publicado: (2021)

Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients
por: Schmidt, Bernd, et al.
Publicado: (2015)

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
por: Yi, Zongbi, et al.
Publicado: (2020)

A systematic review and meta-analysis of circulating cell-free DNA as a diagnostic biomarker for non-small cell lung cancer
por: He, Xin, et al.
Publicado: (2022)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer
por: Cui, Shaohua, et al.
Publicado: (2016)

Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naïve Stage IV Non-Small Cell Lung Cancer Patients
por: Kim, Bo-Guen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ocppe9535hc8i8455ovead9u1l